![]() The story looked even better with patients experiencing a 50% improvement in EASI score - 42.9% of patients treated with RPT193 achieved this marked improvement compared to only 10% of patients in the placebo group. That was more than twice the 17% improvement seen in patients on a placebo. Patients treated with the company's experimental drug achieved a 36.3% improvement in the Eczema Area and Severity Index (EASI) score from baseline. You'd expect that RAPT's results from the early-stage study of RPT193 had to be fantastic for the biotech stock to more than double. The huge gain came after the company announced positive top-line results from a phase 1b clinical study evaluating RPT193 in treating moderate-to-severe atopic dermatitis. ![]() ![]() RAPT Therapeutics ( NASDAQ:RAPT) stock was crushing it on Monday, with shares skyrocketing 110.4% as of 11:59 a.m. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. ![]() Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |